welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggest

Results of the Phase 2 MoveDMD trial showed that Catabasis Pharmaceuticals’ candidate drug edasalonexent (CAT-1004) can reduce the rate of functional decline in boys ages 4–7 with Duchenne muscular dystrophy (DMD).

The recent findings will be subject of a presentation titled, “MoveDMD: Phase 2 Trial of Edasalonexent, an NF-kB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,” delivered by Joanne Donovan, MD, PhD, chief medical officer at Catabasis, during the 2017 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference, June 29–July 2 in Chicago.

Edasalonexent Could Reduce Functional Decline In Boys With DMD, MoveDMD Phase 2 Results Suggest